Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Primary Myelofibrosis | 21 | 2024 | 210 | 2.040 |
Why?
|
Myeloproliferative Disorders | 18 | 2022 | 609 | 1.760 |
Why?
|
Janus Kinase 2 | 26 | 2021 | 542 | 1.570 |
Why?
|
Leukemia, Myeloid, Acute | 31 | 2024 | 3602 | 1.530 |
Why?
|
Polycythemia Vera | 15 | 2022 | 160 | 1.420 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2024 | 1547 | 1.290 |
Why?
|
Thrombocythemia, Essential | 11 | 2022 | 107 | 1.170 |
Why?
|
Myelodysplastic Syndromes | 10 | 2024 | 1394 | 0.750 |
Why?
|
fms-Like Tyrosine Kinase 3 | 7 | 2023 | 495 | 0.550 |
Why?
|
Asparaginase | 3 | 2024 | 240 | 0.520 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2006 | 221 | 0.490 |
Why?
|
Pyrimidines | 10 | 2024 | 3016 | 0.480 |
Why?
|
Protein Kinase Inhibitors | 15 | 2023 | 5643 | 0.470 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 685 | 0.470 |
Why?
|
Antineoplastic Agents | 20 | 2022 | 13630 | 0.440 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 223 | 0.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 12 | 2022 | 5649 | 0.370 |
Why?
|
Leukemia, Myeloid | 3 | 2019 | 695 | 0.360 |
Why?
|
Fusion Proteins, bcr-abl | 4 | 2021 | 431 | 0.350 |
Why?
|
Mastocytosis, Systemic | 2 | 2024 | 102 | 0.350 |
Why?
|
Janus Kinases | 5 | 2020 | 250 | 0.350 |
Why?
|
Antibodies, Bispecific | 3 | 2021 | 191 | 0.340 |
Why?
|
Point Mutation | 4 | 2010 | 1594 | 0.330 |
Why?
|
Remission Induction | 14 | 2023 | 2392 | 0.330 |
Why?
|
Hematologic Neoplasms | 6 | 2018 | 1895 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2006 | 2418 | 0.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11712 | 0.290 |
Why?
|
Enzyme Inhibitors | 2 | 2010 | 3726 | 0.280 |
Why?
|
Aminoglycosides | 2 | 2006 | 163 | 0.270 |
Why?
|
Mutation, Missense | 6 | 2011 | 2566 | 0.260 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 629 | 0.260 |
Why?
|
Mutation | 21 | 2024 | 29932 | 0.260 |
Why?
|
Geriatric Assessment | 3 | 2022 | 1405 | 0.250 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 886 | 0.250 |
Why?
|
Transplantation, Homologous | 9 | 2022 | 4810 | 0.250 |
Why?
|
World Health Organization | 1 | 2010 | 1312 | 0.230 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 98 | 0.220 |
Why?
|
Neutropenia | 1 | 2009 | 884 | 0.220 |
Why?
|
Nitriles | 3 | 2024 | 956 | 0.220 |
Why?
|
Philadelphia Chromosome | 3 | 2022 | 117 | 0.220 |
Why?
|
Pyrazoles | 3 | 2024 | 1999 | 0.210 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 2 | 2013 | 37 | 0.210 |
Why?
|
Medical Oncology | 6 | 2024 | 2313 | 0.210 |
Why?
|
Benzamides | 4 | 2017 | 1369 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 9 | 2014 | 4490 | 0.200 |
Why?
|
Aged, 80 and over | 34 | 2024 | 58995 | 0.190 |
Why?
|
Humans | 112 | 2024 | 760621 | 0.190 |
Why?
|
Blast Crisis | 3 | 2011 | 101 | 0.180 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2013 | 251 | 0.180 |
Why?
|
Aged | 50 | 2024 | 169152 | 0.170 |
Why?
|
Prognosis | 23 | 2024 | 29658 | 0.170 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 316 | 0.170 |
Why?
|
Middle Aged | 53 | 2024 | 220352 | 0.170 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2011 | 92 | 0.160 |
Why?
|
Myeloid Cells | 3 | 2017 | 820 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 727 | 0.160 |
Why?
|
STAT Transcription Factors | 3 | 2018 | 188 | 0.160 |
Why?
|
Leukemia | 3 | 2016 | 1520 | 0.160 |
Why?
|
Mycoses | 1 | 2022 | 387 | 0.160 |
Why?
|
Amino Acid Substitution | 6 | 2011 | 1737 | 0.160 |
Why?
|
Neoplasms | 7 | 2022 | 22072 | 0.150 |
Why?
|
Adult | 48 | 2024 | 219994 | 0.150 |
Why?
|
Thrombocytosis | 4 | 2017 | 82 | 0.150 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 180 | 0.150 |
Why?
|
Piperazines | 4 | 2016 | 2525 | 0.150 |
Why?
|
Janus Kinase 1 | 1 | 2017 | 107 | 0.150 |
Why?
|
Hospice Care | 1 | 2024 | 692 | 0.140 |
Why?
|
Receptors, Thrombopoietin | 4 | 2016 | 161 | 0.140 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 2803 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1977 | 0.140 |
Why?
|
Survival Rate | 12 | 2022 | 12808 | 0.140 |
Why?
|
Disease-Free Survival | 8 | 2023 | 6828 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 2 | 2024 | 3735 | 0.130 |
Why?
|
Cytarabine | 5 | 2019 | 696 | 0.130 |
Why?
|
Male | 57 | 2024 | 359744 | 0.130 |
Why?
|
Female | 60 | 2024 | 391270 | 0.130 |
Why?
|
Eosinophilia | 1 | 2020 | 559 | 0.130 |
Why?
|
Lethargy | 1 | 2015 | 43 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Arabinonucleosides | 1 | 2014 | 34 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2014 | 111 | 0.120 |
Why?
|
Gene Frequency | 3 | 2018 | 3615 | 0.120 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 225 | 0.120 |
Why?
|
Cell Cycle Proteins | 2 | 2024 | 3446 | 0.120 |
Why?
|
Stem Cell Transplantation | 3 | 2018 | 1599 | 0.120 |
Why?
|
Treatment Outcome | 22 | 2024 | 65017 | 0.120 |
Why?
|
Young Adult | 19 | 2024 | 58741 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 414 | 0.120 |
Why?
|
Quality of Life | 7 | 2023 | 13308 | 0.110 |
Why?
|
Early Termination of Clinical Trials | 1 | 2013 | 71 | 0.110 |
Why?
|
Receptor, Notch2 | 1 | 2014 | 87 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2018 | 510 | 0.110 |
Why?
|
Survival Analysis | 9 | 2018 | 10182 | 0.110 |
Why?
|
STAT5 Transcription Factor | 1 | 2014 | 264 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Translocation, Genetic | 3 | 2009 | 1388 | 0.110 |
Why?
|
Anemia | 1 | 2022 | 1511 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2128 | 0.100 |
Why?
|
Serotonin Syndrome | 1 | 2012 | 18 | 0.100 |
Why?
|
Hospitalization | 4 | 2024 | 10790 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1440 | 0.100 |
Why?
|
Proline | 1 | 2013 | 457 | 0.100 |
Why?
|
Alternative Splicing | 2 | 2014 | 1091 | 0.100 |
Why?
|
Azacitidine | 2 | 2024 | 334 | 0.100 |
Why?
|
Retrospective Studies | 19 | 2022 | 80372 | 0.100 |
Why?
|
Receptors, Cytokine | 2 | 2009 | 258 | 0.100 |
Why?
|
Methylene Blue | 1 | 2012 | 157 | 0.100 |
Why?
|
Aminopyridines | 1 | 2015 | 564 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1864 | 0.100 |
Why?
|
Ifosfamide | 1 | 2012 | 232 | 0.100 |
Why?
|
Anaphylaxis | 1 | 2018 | 755 | 0.100 |
Why?
|
Adolescent | 19 | 2024 | 87810 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1480 | 0.090 |
Why?
|
Dexamethasone | 2 | 2015 | 1927 | 0.090 |
Why?
|
Signal Transduction | 9 | 2023 | 23376 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3584 | 0.090 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2017 | 1652 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 4899 | 0.090 |
Why?
|
Hydroxamic Acids | 1 | 2013 | 482 | 0.090 |
Why?
|
Calreticulin | 3 | 2016 | 115 | 0.090 |
Why?
|
Tretinoin | 1 | 2013 | 519 | 0.090 |
Why?
|
Antibodies, Monoclonal | 2 | 2006 | 9185 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1139 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2015 | 858 | 0.090 |
Why?
|
Nuclear Proteins | 3 | 2024 | 5791 | 0.090 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15840 | 0.090 |
Why?
|
Patients | 1 | 2016 | 906 | 0.090 |
Why?
|
Neurotoxicity Syndromes | 1 | 2013 | 299 | 0.080 |
Why?
|
Intensive Care Units | 2 | 2021 | 3736 | 0.080 |
Why?
|
Anthracyclines | 2 | 2023 | 283 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5253 | 0.080 |
Why?
|
RNA Splicing | 1 | 2013 | 915 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1416 | 0.080 |
Why?
|
Terminal Care | 2 | 2024 | 1758 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1386 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4283 | 0.080 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2009 | 347 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 772 | 0.080 |
Why?
|
Risk Factors | 13 | 2024 | 74359 | 0.070 |
Why?
|
Thrombosis | 3 | 2018 | 3052 | 0.070 |
Why?
|
Headache | 1 | 2015 | 1249 | 0.070 |
Why?
|
Patient Care Team | 1 | 2018 | 2511 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1363 | 0.070 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2009 | 635 | 0.070 |
Why?
|
DNA-Binding Proteins | 3 | 2024 | 9585 | 0.070 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 877 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 1056 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1898 | 0.070 |
Why?
|
Vincristine | 2 | 2022 | 1039 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2013 | 9276 | 0.070 |
Why?
|
DNA Mutational Analysis | 6 | 2014 | 4107 | 0.060 |
Why?
|
Tenascin | 1 | 2005 | 62 | 0.060 |
Why?
|
Fatigue | 2 | 2017 | 1544 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5425 | 0.060 |
Why?
|
Incidence | 5 | 2024 | 21392 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1511 | 0.060 |
Why?
|
Indoles | 1 | 2013 | 1829 | 0.060 |
Why?
|
Retreatment | 2 | 2016 | 600 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2024 | 7818 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2017 | 8552 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7408 | 0.060 |
Why?
|
Catalysis | 1 | 2006 | 775 | 0.060 |
Why?
|
Splenomegaly | 2 | 2015 | 189 | 0.060 |
Why?
|
Follow-Up Studies | 9 | 2019 | 39261 | 0.060 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2005 | 286 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 184 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2020 | 1596 | 0.060 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 1993 | 0.060 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2010 | 929 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2004 | 192 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2006 | 321 | 0.060 |
Why?
|
Staurosporine | 1 | 2004 | 242 | 0.060 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 2 | 2018 | 105 | 0.050 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2005 | 385 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2006 | 3602 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3610 | 0.050 |
Why?
|
Recurrence | 4 | 2018 | 8482 | 0.050 |
Why?
|
Boronic Acids | 3 | 2013 | 914 | 0.050 |
Why?
|
Bone Marrow | 4 | 2018 | 2912 | 0.050 |
Why?
|
Transplantation Conditioning | 2 | 2022 | 1588 | 0.050 |
Why?
|
Cell Lineage | 2 | 2016 | 2533 | 0.050 |
Why?
|
Acute Disease | 3 | 2019 | 7269 | 0.050 |
Why?
|
Hematopoiesis | 3 | 2009 | 2050 | 0.050 |
Why?
|
Brain Diseases | 1 | 2012 | 1540 | 0.050 |
Why?
|
Clone Cells | 1 | 2006 | 1660 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7475 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2018 | 367 | 0.050 |
Why?
|
B-Lymphocytes | 3 | 2021 | 4742 | 0.050 |
Why?
|
Disease Management | 2 | 2024 | 2514 | 0.050 |
Why?
|
Pyrazines | 3 | 2013 | 1199 | 0.050 |
Why?
|
Phosphoproteins | 2 | 2024 | 2440 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3164 | 0.050 |
Why?
|
Homozygote | 3 | 2014 | 1788 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2021 | 11481 | 0.050 |
Why?
|
Microcirculation | 1 | 2005 | 1278 | 0.050 |
Why?
|
Gene Expression Profiling | 5 | 2016 | 9411 | 0.040 |
Why?
|
Karyotyping | 2 | 2014 | 1171 | 0.040 |
Why?
|
Stromal Cells | 1 | 2005 | 1326 | 0.040 |
Why?
|
Phenotype | 4 | 2016 | 16546 | 0.040 |
Why?
|
Drug Synergism | 2 | 2015 | 1754 | 0.040 |
Why?
|
Blood Vessels | 1 | 2005 | 1112 | 0.040 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2019 | 29 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 675 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2007 | 1535 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2019 | 6068 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6538 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 8035 | 0.040 |
Why?
|
Comorbidity | 3 | 2022 | 10551 | 0.040 |
Why?
|
Age Factors | 5 | 2020 | 18416 | 0.040 |
Why?
|
Histamine Antagonists | 1 | 2018 | 90 | 0.040 |
Why?
|
Bone Marrow Cells | 2 | 2021 | 2414 | 0.040 |
Why?
|
Protein Conformation | 1 | 2006 | 3969 | 0.040 |
Why?
|
Prospective Studies | 6 | 2023 | 54303 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4591 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9467 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5794 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2005 | 1375 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14495 | 0.040 |
Why?
|
Animals | 8 | 2018 | 167963 | 0.040 |
Why?
|
Dioxygenases | 2 | 2011 | 335 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 149 | 0.040 |
Why?
|
Sequence Deletion | 3 | 2009 | 1493 | 0.040 |
Why?
|
Hydrolases | 1 | 2018 | 146 | 0.040 |
Why?
|
Patient Transfer | 1 | 2024 | 779 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 8056 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1407 | 0.040 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2417 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2004 | 1613 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2014 | 2698 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2022 | 749 | 0.030 |
Why?
|
Genetic Testing | 1 | 2010 | 3531 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2020 | 613 | 0.030 |
Why?
|
Etoposide | 1 | 2017 | 630 | 0.030 |
Why?
|
Anxiety | 2 | 2023 | 4538 | 0.030 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1677 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 2015 | 66 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2018 | 10446 | 0.030 |
Why?
|
Mental Disorders | 1 | 2015 | 6796 | 0.030 |
Why?
|
Sphingosine | 1 | 1997 | 308 | 0.030 |
Why?
|
Administration, Oral | 2 | 2013 | 4035 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Piracetam | 1 | 2015 | 88 | 0.030 |
Why?
|
Transcription Factors | 2 | 2014 | 12103 | 0.030 |
Why?
|
Spleen | 2 | 2015 | 2298 | 0.030 |
Why?
|
Mice | 6 | 2018 | 81208 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2018 | 727 | 0.030 |
Why?
|
Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
Endothelium, Vascular | 2 | 2004 | 4433 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2018 | 22053 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3711 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 353 | 0.030 |
Why?
|
Nootropic Agents | 1 | 2015 | 157 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 830 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 184 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12626 | 0.030 |
Why?
|
Exons | 2 | 2011 | 2388 | 0.030 |
Why?
|
Hydroxyurea | 1 | 2015 | 282 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1722 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2018 | 1871 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 713 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
Disease Progression | 5 | 2012 | 13502 | 0.030 |
Why?
|
Granulocytes | 2 | 2006 | 551 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2011 | 1745 | 0.030 |
Why?
|
Risk Assessment | 4 | 2017 | 24123 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11152 | 0.030 |
Why?
|
Time Factors | 4 | 2019 | 40165 | 0.030 |
Why?
|
Daunorubicin | 1 | 2012 | 156 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 816 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13314 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2421 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.030 |
Why?
|
Child | 4 | 2024 | 79806 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 372 | 0.020 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 317 | 0.020 |
Why?
|
Repressor Proteins | 2 | 2014 | 2981 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1195 | 0.020 |
Why?
|
Azepines | 1 | 2014 | 330 | 0.020 |
Why?
|
Germ-Line Mutation | 2 | 2011 | 1841 | 0.020 |
Why?
|
United States | 5 | 2022 | 72461 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1185 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
Mast Cells | 1 | 2018 | 1390 | 0.020 |
Why?
|
Body Mass Index | 2 | 2023 | 12914 | 0.020 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 453 | 0.020 |
Why?
|
Depression | 2 | 2023 | 8044 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 524 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2015 | 16939 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12531 | 0.020 |
Why?
|
Research Design | 2 | 2018 | 6180 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2014 | 2828 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2017 | 1268 | 0.020 |
Why?
|
Craniotomy | 1 | 2015 | 741 | 0.020 |
Why?
|
Cytokines | 3 | 2013 | 7343 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 61 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2011 | 271 | 0.020 |
Why?
|
Length of Stay | 1 | 2024 | 6479 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2014 | 646 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3880 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12427 | 0.020 |
Why?
|
Internet | 2 | 2016 | 3078 | 0.020 |
Why?
|
Hemoglobins | 2 | 2006 | 1521 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1565 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8555 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1248 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5523 | 0.020 |
Why?
|
Metaphase | 1 | 2009 | 144 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1617 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2016 | 2435 | 0.020 |
Why?
|
Quality Improvement | 1 | 2024 | 3836 | 0.020 |
Why?
|
Genotype | 3 | 2011 | 12960 | 0.020 |
Why?
|
Heterozygote | 2 | 2006 | 2798 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 1827 | 0.020 |
Why?
|
Cohort Studies | 4 | 2015 | 41335 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3387 | 0.020 |
Why?
|
Idarubicin | 1 | 2008 | 59 | 0.020 |
Why?
|
Triazoles | 1 | 2014 | 904 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1446 | 0.020 |
Why?
|
Trisomy | 1 | 2009 | 260 | 0.020 |
Why?
|
Mixed Function Oxygenases | 1 | 2009 | 265 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2009 | 281 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 884 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1755 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2011 | 4713 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2014 | 1131 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2209 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1719 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2049 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2013 | 965 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2648 | 0.020 |
Why?
|
Fibrinogen | 1 | 2010 | 886 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2009 | 388 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 17790 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 1529 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6771 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3280 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 1997 | 2698 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3905 | 0.020 |
Why?
|
Mice, Inbred BALB C | 2 | 2006 | 6216 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9280 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2116 | 0.020 |
Why?
|
Immunotoxins | 1 | 2006 | 175 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 351 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2011 | 15789 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1855 | 0.020 |
Why?
|
Sex Chromosome Aberrations | 1 | 2006 | 116 | 0.020 |
Why?
|
Cell Line | 2 | 2014 | 15620 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6544 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6898 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3242 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3442 | 0.010 |
Why?
|
Phosphorylation | 2 | 2006 | 8313 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3925 | 0.010 |
Why?
|
Bone Marrow Diseases | 1 | 2006 | 232 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 2004 | 192 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1881 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 2006 | 468 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 2009 | 7593 | 0.010 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2004 | 193 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2262 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9716 | 0.010 |
Why?
|
Cell Survival | 1 | 2014 | 5797 | 0.010 |
Why?
|
Isoantigens | 1 | 2006 | 552 | 0.010 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 256 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 488 | 0.010 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2004 | 452 | 0.010 |
Why?
|
Pruritus | 1 | 2006 | 377 | 0.010 |
Why?
|
Zinc Fingers | 1 | 2004 | 568 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 2005 | 426 | 0.010 |
Why?
|
Megakaryocytes | 1 | 2006 | 565 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2005 | 1600 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12922 | 0.010 |
Why?
|
Membrane Proteins | 2 | 2014 | 7850 | 0.010 |
Why?
|
Palliative Care | 1 | 2016 | 3607 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2009 | 4625 | 0.010 |
Why?
|
DNA Primers | 1 | 2005 | 2819 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2005 | 1526 | 0.010 |
Why?
|
Mitosis | 1 | 2005 | 1191 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15687 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3775 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2005 | 4169 | 0.010 |
Why?
|
Apoptosis | 1 | 2015 | 9501 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10344 | 0.010 |
Why?
|
Cell Division | 1 | 2006 | 4463 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2005 | 2506 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10181 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9631 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2006 | 2693 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2006 | 1974 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2014 | 8515 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3315 | 0.010 |
Why?
|
Transfection | 1 | 2005 | 5781 | 0.010 |
Why?
|
Disabled Persons | 1 | 2007 | 1223 | 0.010 |
Why?
|
Motor Activity | 1 | 2007 | 2687 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2006 | 3380 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2006 | 2825 | 0.010 |
Why?
|
Medicare | 1 | 2014 | 6786 | 0.010 |
Why?
|
Sphingolipids | 1 | 1997 | 173 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2006 | 18137 | 0.010 |
Why?
|
Genome, Human | 1 | 2009 | 4417 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20080 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2006 | 3707 | 0.010 |
Why?
|
Models, Molecular | 1 | 2005 | 5434 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1997 | 856 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1997 | 814 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2005 | 3486 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12446 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 13451 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20509 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12159 | 0.010 |
Why?
|
Chronic Disease | 1 | 2007 | 9287 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 13981 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2006 | 18957 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 6551 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11903 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36290 | 0.000 |
Why?
|
Child, Preschool | 1 | 2006 | 42063 | 0.000 |
Why?
|